These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11489318)

  • 1. Preparation, characterization and in vivo evaluation of 120-day poly(D,L-lactide) leuprolide microspheres.
    Woo BH; Kostanski JW; Gebrekidan S; Dani BA; Thanoo BC; DeLuca PP
    J Control Release; 2001 Aug; 75(3):307-15. PubMed ID: 11489318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel in vitro release technique for peptide containing biodegradable microspheres.
    Kostanski JW; DeLuca PP
    AAPS PharmSciTech; 2000 Mar; 1(1):E4. PubMed ID: 14727853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro characterization and in vivo testosterone suppression of 6-month release poly(D,L-lactide) leuprolide microspheres.
    Woo BH; Na KH; Dani BA; Jiang G; Thanoo BC; DeLuca PP
    Pharm Res; 2002 Apr; 19(4):546-50. PubMed ID: 12033393
    [No Abstract]   [Full Text] [Related]  

  • 4. Preparation, characterization, and in vitro evaluation of 1- and 4-month controlled release orntide PLA and PLGA microspheres.
    Kostanski JW; Thanoo BC; DeLuca PP
    Pharm Dev Technol; 2000; 5(4):585-96. PubMed ID: 11109259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres.
    Ravivarapu HB; Burton K; DeLuca PP
    Eur J Pharm Biopharm; 2000 Sep; 50(2):263-70. PubMed ID: 10962237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Orntide microspheres in a rat animal model and correlation to in vitro release profiles.
    Kostanski JW; Dani BA; Reynolds GA; Bowers CY; DeLuca PP
    AAPS PharmSciTech; 2000 Oct; 1(4):E27. PubMed ID: 14727892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing initial release of peptide from poly(d,l-lactide-co-glycolide) (PLGA) microspheres by addition of a porosigen and increasing drug load.
    Ravivarapu HB; Lee H; DeLuca PP
    Pharm Dev Technol; 2000; 5(2):287-96. PubMed ID: 10810758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hetero-stereocomplexes of D-poly(lactic acid) and the LHRH analogue leuprolide. Application in controlled release.
    Slager J; Domb AJ
    Eur J Pharm Biopharm; 2004 Nov; 58(3):461-9. PubMed ID: 15451519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodegradable PLGA microspheres as a sustained release system for a new luteinizing hormone-releasing hormone (LHRH) antagonist.
    Du L; Cheng J; Chi Q; Qie J; Liu Y; Mei X
    Chem Pharm Bull (Tokyo); 2006 Sep; 54(9):1259-65. PubMed ID: 16946531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterostereocomplexes prepared from d-PLA and l-PLA and leuprolide. II. Release of leuprolide.
    Slager J; Domb AJ
    Biomacromolecules; 2003; 4(5):1316-20. PubMed ID: 12959600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended release peptide delivery systems through the use of PLGA microsphere combinations.
    Burton KW; Shameem M; Thanoo BC; DeLuca PP
    J Biomater Sci Polym Ed; 2000; 11(7):715-29. PubMed ID: 11011769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In situ forming microparticle system for controlled delivery of leuprolide acetate: influence of the formulation and processing parameters.
    Luan X; Bodmeier R
    Eur J Pharm Sci; 2006 Feb; 27(2-3):143-9. PubMed ID: 16243496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the concurrent LHRH antagonist administration with a LHRH superagonist in rats.
    Kostanski JW; Dani BA; Schrier B; DeLuca PP
    Pharm Res; 2000 Apr; 17(4):445-50. PubMed ID: 10870989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide.
    Ravivarapu HB; Moyer KL; Dunn RL
    Int J Pharm; 2000 Jan; 194(2):181-91. PubMed ID: 10692642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres.
    Blanco-Príeto MJ; Campanero MA; Besseghir K; Heimgatner F; Gander B
    J Control Release; 2004 May; 96(3):437-48. PubMed ID: 15120900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro/in-vivo studies of the biodegradable poly-(D,L-lactide-co-glycolide) microspheres of a novel luteinizing hormone-releasing hormone antagonist for prostate cancer treatment.
    Du L; Mei X; Wang C; Li X; Zhang F; Jin Y
    Anticancer Drugs; 2011 Mar; 22(3):262-72. PubMed ID: 21360849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Manufacturing Variables and Raw Materials on the Composition-Equivalent PLGA Microspheres for 1-Month Controlled Release of Leuprolide.
    Zhou J; Walker J; Ackermann R; Olsen K; Hong JKY; Wang Y; Schwendeman SP
    Mol Pharm; 2020 May; 17(5):1502-1515. PubMed ID: 32074448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New long-acting injectable microspheres prepared by IVL-DrugFluidic™ system: 1-month and 3-month in vivo drug delivery of leuprolide.
    Kim M; Kim JH; Kim S; Maharjan R; Kim NA; Jeong SH
    Int J Pharm; 2022 Jun; 622():121875. PubMed ID: 35636628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microsphere delivery of Risperidone as an alternative to combination therapy.
    D'Souza S; Faraj J; DeLuca P
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo evaluation of solid lipid microparticles and hybrid polymer-lipid microparticles for sustained delivery of leuprolide.
    Wu C; Luo X; Baldursdottir SG; Yang M; Sun X; Mu H
    Eur J Pharm Biopharm; 2019 Sep; 142():315-321. PubMed ID: 31299277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.